Dual antiretroviral therapy for HIV infection

Soriano, Vincent; Fernández-Montero, José Vicente; Benítez-Gutiérrez, Laura; Mendoza, Carmen de; Arias, Ana; Barreiro, Pablo; Peña, José M.; Labarga, Pablo

doi:10.1080/14740338.2017.1343300

Cited by 51 publications

(44 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a randomized pilot clinical trial [23], this strategy was also non-inferior to continuation of standard three-drug maintenance therapy. Due to its favorable metabolic profile, the lack of major toxicities and the low projected costs, if ongoing trials will confirm its efficacy, the combination of lamivudine plus dolutegravir could change the management of HIV-infection in next years, as two systematic review on this subject also evidenced [24, 25].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

et al. 2019

View full text Add to dashboard Cite

BackgroundDirect comparisons between lamivudine plus bPIs and lamivudine plus dolutegravir as maintenance strategies in virologically-suppressed HIV positive patients are lacking.MethodsTime to treatment discontinuation (TD) and virological failure (VF) were compared in a cohort of HIV+ patients on a virologically-effective ART starting lamivudine with either darunavir/r, atazanavir/r or dolutegravir. Changes in laboratory parameters were also evaluated.ResultsFour-hundred-ninety-four patients were analyzed (170 switching to darunavir/r, 141 to atazanavir/r, 183 to dolutegravir): median age was 49 years, with 8 years since ART start. Groups differed for age, HIV-risk factor, time since HIV-diagnosis and on ART, previous therapy and reasons for switching.Estimated proportions free from TD at week 48 and 96 were 79.8 and 48.3% of patients with darunavir/r, 87.0 and 70.9% with atazanavir/r, and 88.2 and 82.6% with dolutegravir, respectively (p < 0.001). Calendar years, HIV-risk factor, higher baseline cholesterol and an InSTI-based previous regimen predicted TD, whereas lamivudine+dolutegravir therapy and previous tenofovir use were protective. VF was the cause of TD in 6/123 cases with darunavir/r, 4/97 with atazanavir/r and 3/21 with dolutegravir. Other main reasons for TD were: toxicity (43.1% with darunavir/r, 39.2% with atazanavir/r, 52.4% with dolutegravir), further simplification (36.6% with darunavir/r, 30.9% with atazanavir/r, 14.3% with dolutegravir). Incidence of VF did not differ among study groups (p = 0.747). No factor could predict VF.Lipid profile improved in the dolutegravir group, whereas renal function improved in the bPIs groups.ConclusionsIn real practice, a switch to lamivudine+dolutegravir showed similar efficacy but longer durability than a switch to lamivudine+bPIs.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

et al. 2019

View full text Add to dashboard Cite

show abstract

“…These include drugs that have sustained-release, polypills and dual inhibitors. The dual inhibitors contain a pharmacophore that allows it to bind to two different targets to produce additive or synergistic effects [ 132 ]. The following two different approaches were explored to target IN and RT enzymes, and IN catalytic site and LEDGF-binding site to develop dual inhibitors.…”

Section: Inis Approved For Clinical Applicationmentioning

confidence: 99%

Recent Advances in the Discovery of Small-Molecule Inhibitors of HIV-1 Integrase

Choi

Mallareddy

et al. 2018

Future Sci. OA

View full text Add to dashboard Cite

AIDS caused by the infection of HIV is a prevalent problem today. Rapid development of drug resistance to existing drug classes has called for the discovery of new targets. Within the three major enzymes (i.e., HIV-1 protease, HIV-1 reverse transcriptase and HIV-1 integrase [IN]) of the viral replication cycle, HIV-1 IN has been of particular interest due to the absence of human cellular homolog. HIV-1 IN catalyzes the integration of viral genetic material with the host genome, a key step in the viral replication process. Several novel classes of HIV IN inhibitors have been explored by targeting different sites on the enzyme. This review strives to provide readers with updates on the recent developments of HIV-1 IN inhibitors.

show abstract

“…Since the emergence of ART, there has been a lot of improvements in the safety and e cacy of ART (8,9).…”

Section: Introductionmentioning

confidence: 99%

Psychometric assessment of translated Urdu version of WHOQOL-HIV BREF among patients living with HIV

Ahmed

Saqlain

Akhtar

et al. 2020

Preprint

View full text Add to dashboard Cite

ObjectiveThe Low Middle Income Countries (LMIC) like Pakistan are facing an escalation in the number of HIV cases, approximately more than 180,000 people are currently living with HIV/AIDS (PLWHA). Currently, no HIV specific Health Related Quality of Life (HRQoL) tool is validated in Pakistan; therefore, the current analysis was aimed at translating and examining the psychometric properties of the Urdu version of WHOQOL HIV BREF among HIV patients of Pakistan.MethodsThe standard forward-backwards translation technique was used for Urdu translation of the instrument. Based on the principle of 5 subjects minimally for each item, a sample of 182 patients were recruited by employing a universal random sampling technique. Data were analysed to measure reliability, internal consistency, known-group, multivariable linear regression and construct validity. Results High internal consistency 0.93 (Cronbach alpha) was found for all WHOQOL HIV Bref facets. The test-retest reliability analysis demonstrated a statistically significant Interclass Correlation Coefficient (ICC) ranged from 0.88 – 0.98 (p < 0.001). In known group validity, lower CD-4 lymphocytes count was significantly related to poor scores for all six domains (p < 0.001). Similarly, symptomatic subjects had significantly lower scores compared to asymptomatic subjects on the physical, psychological, social relationship and independence domains (p < 0.05). Results also revealed a statistically significant positive correlation of all six domains with CD4 count (p < 0.001), exhibiting patients with higher CD-4 lymphocytes count will have higher mean scores of all six domains. Factor analysis revealed 5 domains, including Physical health, Psychological health, Social relationship, Environmental, and Spiritual health. When all domains were assessed together via Multivariable linear regression analysis; only physical, psychological health and environment health domains were found significantly associated with higher CD-4 lymphocytes count (Beta = 0.121, p < 0.001, Beta = 0.103, p = 0.002, and Beta = 0.032, p = 0.032).ConclusionFindings suggested that the Urdu version of WHOQOL HIV Bref is a psychometrically valid tool for measuring HRQoL.

show abstract

Dual antiretroviral therapy for HIV infection

Cited by 51 publications

References 65 publications

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

Recent Advances in the Discovery of Small-Molecule Inhibitors of HIV-1 Integrase

Psychometric assessment of translated Urdu version of WHOQOL-HIV BREF among patients living with HIV

Contact Info

Product

Resources

About